Multitarget drugs: Focus on the NO-donor hybrid drugs. Pure Appl. Chem. 2008; 80 :1693–1701.Gasco, A.; Boschi, D.; Chegaev, K.; Cena, C.; Di Stilo, A.; Frut- tero, R.; Lazzarato, L.; Rolando, B.; Tosco, P. Multitarget drugs: Focus on the NO-donor hybrid drugs. Pure...
include; overcoming clonal heterogeneity, lower risk of multi-drug resistance (MDR), decreased drug toxicity, and thereby lower side effects. In this study, we'll discuss about multi-target drugs, their benefits in improving cancer treatments, and recent advances in the field of multi-targeted dr...
Antonio M. G., de DiegoSilvia, LorrioJesús M., Hernández-GuijoLuis, GandíaAntonio G., García. Multitarget Drugs for Stabilization of Calcium Cycling and Neuroprotection in Neurodegenerative Diseases and Stroke. 2012:, 123-200. /Antonio M. G.de Diego, SilviaLorrio, Jesús M.Hernández-...
In recent years, multi-target drugs - that is, drugs that affect more than one gene or protein - have been moving into the focus of drug discovery and development [1, 2]. The first reason for this phenomenon is that multi-target drugs have been found to be more effective than single-...
Current Status and Future Direction of Multi-targeted Drugs in the Era of Personalized Therapy —Overview of Advances in Multi-targeted Therapy in Non-smal... Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, ...
Pursuing the widespread interest on multi-target drugs to combat Alzheimers disease (AD), a new series of hybrids was designed and developed based on the repositioning of the well-known acetylcholinesterase (AChE) inhibitor, tacrine (TAC), by its coupling to benzofuran (BF) derivatives. The BF...
Dipeptidyl peptidase-4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase -4抑制剂:多靶点药物,不仅仅是降糖药) Zhao Y,Yang L,Zhou Z.Dipeptidyl peptidase-4 inhibitors:multitarget drugs,not only antidiabetes drugs[J].J Diabetes,2014,6(1):21-29... Yunjuan Zhao...
Thus, the development of multitarget drugs which are involved in both pathways might represent a promising therapeutic strategy. Accordingly, reported here in is the discovery of 6-amino-4-phenyl-3,4-dihydro-1,3,5-triazin-2(1H)-ones as the first class of molecules able to simultaneously ...
Despite considerable progress in genome- and proteome-based high-throughput screening methods and rational drug design, the number of successful single target drugs did not increase appreciably during the past decade. Network models suggest that partial inhibition of a surprisingly small number of target...
Designing multi-target drugs for complex diseases The transition from the single-target to the multi-target concept for drug design Traditionally drugs have been designed with the aim of targeting a single biological entity, usually a protein (the so-called “on-target”), with high selectivity ...